Daniel Skovronsky M.'s Insider Trades & SAST Disclosures
Daniel Skovronsky M.'s most recent trade in Lilly(Eli) & Co was a trade of 18,771 Common Stock done at an average price of $868.9 . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Daniel Skovronsky M..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Grant, award, or other acquisition of securities at price $ 868.91 per share. | 10 Feb 2025 | 18,771 | 136,660 (0%) | 0% | 868.9 | 16,310,400 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 12,684 | 12,684 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Sale of securities on an exchange or to another person at price $ 862.69 per share. | 10 Feb 2025 | 3,950 | 118,938 (0%) | 0% | 862.7 | 3,407,626 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Sale of securities on an exchange or to another person at price $ 865.76 per share. | 10 Feb 2025 | 710 | 117,888 (0%) | 0% | 865.8 | 614,690 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Sale of securities on an exchange or to another person at price $ 863.97 per share. | 10 Feb 2025 | 340 | 118,598 (0%) | 0% | 864.0 | 293,750 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 8,989 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 8,989 | 126,892 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Payment of exercise price or tax liability using portion of securities received from the company at price $ 811.21 per share. | 01 Feb 2025 | 4,003 | 122,888 (0%) | 0% | 811.2 | 3,247,272 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Sep 2024 | 5,724 | 117,903 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Sep 2024 | 111 | 123,627 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 86,010 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 9,941 | 115,262 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Skovronsky Daniel M. | EVP, CSO & Pres. LRL & LLY Imm | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 9,941 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel Skovronsky M. | EVP, CSO & Pres. LRL & LLY Imm | Payment of exercise price or tax liability using portion of securities received from the company at price $ 645.61 per share. | 01 Feb 2024 | 4,434 | 110,828 (0%) | 0% | 645.6 | 2,862,635 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CS&MO & Pres., LRL | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Nov 2023 | 17 | 105,321 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CS&MO & Pres., LRL | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Aug 2023 | 249 | 105,338 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 70,315 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CS&MO & Pres., LRL | Grant, award, or other acquisition of securities at price $ 345.12 per share. | 10 Feb 2023 | 18,388 | 105,587 (0%) | 0% | 345.1 | 6,346,067 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CS&MO & Pres., LRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 9,941 | 9,941 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CS&MO & Pres., LRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 15,675 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CS&MO & Pres., LRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 15,675 | 94,234 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | EVP, CS&MO & Pres., LRL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 344.15 per share. | 01 Feb 2023 | 7,035 | 87,199 (0%) | 0% | 344.1 | 2,421,095 | Common Stock |
| Myriad Genetics, Inc. | Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 55,164 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | SVP, CS&MO & Pres. LRL | Grant, award, or other acquisition of securities at price $ 243.27 per share. | 09 Feb 2022 | 22,581 | 78,559 (0%) | 0% | 243.3 | 5,493,280 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | SVP, CS&MO & Pres. LRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 15,675 | 15,675 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | SVP, CS&MO & Pres. LRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 18,735 | 64,415 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | SVP, CS&MO & Pres. LRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 18,735 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | SVP, CS&MO & Pres. LRL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 245.39 per share. | 01 Feb 2022 | 8,437 | 55,978 (0%) | 0% | 245.4 | 2,070,355 | Common Stock |
| Lilly(Eli) & Co | Daniel M. Skovronsky | SVP, CSO, and Pres. LRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 18,735 | 18,735 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Daniel M. Skovronsky | SVP, CSO, and Pres. LRL | Grant, award, or other acquisition of securities at price $ 205.77 per share. | 08 Feb 2021 | 18,521 | 115,680 (0%) | 0% | 205.8 | 3,811,066 | Common Stock |
| Myriad Genetics, Inc. | Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2020 | 25,041 | 25,041 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges